Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Cyramza | Ramucirumab | Cancelled | ||||
Alecensaro | Alectinib | Locally advanced or metastatic ALK+ NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
Trelegy Ellipta | fluticasone furoate umeclidinium vilanterol | Chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia (pediatric) | Reimburse with clinical criteria and/or conditions | Complete |